Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study

Development and Validation of 11 Symptom Indexes to Evaluate Response to Chemotherapy for Advanced Cancer

(2017) David Cella et al.   Journal of the National Comprehensive Cancer Network

A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)

(2015) N. I. Cherny et al.   ANNALS OF ONCOLOGY

673 Effects of radium-223 dichloride (Ra-223) on health-related quality of life (HRQoL) assessed by the EQ-5D utility scores in ALSYMPCA

(2015) P. Cislo et al.   EUROPEAN UROLOGY SUPPLEMENTS

Radium-223 dichloride for the treatment of bone metastatic castration-resistant prostate cancer: an evaluation of its safety

(2015) Sten Nilsson   Expert Opinion On Drug Safety

Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: additional analyses from the AFFIRM randomized clinical trial

(2014) D. Cella et al.   ANNALS OF ONCOLOGY

Optimal management of metastatic castration-resistant prostate cancer: Highlights from a European Expert Consensus Panel

(2014) John M. Fitzpatrick et al.   EUROPEAN JOURNAL OF CANCER

Systemic Therapy in Men With Metastatic Castration-Resistant Prostate Cancer: American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guideline

(2014) Ethan Basch et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial

(2014) Peter Hoskin et al.   LANCET ONCOLOGY

Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial

(2014) Oliver Sartor et al.   LANCET ONCOLOGY

A global analysis of multitrial data investigating quality of life and symptoms as prognostic factors for survival in different tumor sites

(2013) Chantal Quinten et al.   CANCER

The Validity and Utility of the MD Anderson Symptom Inventory in Patients With Prostate Cancer: Evidence From the Symptom Outcomes and Practice Patterns (SOAPP) Data From the Eastern Cooperative Oncology Group

(2013) Desiree Jones et al.   Clinical Genitourinary Cancer

Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy

(2013) Stephen Harland et al.   EUROPEAN JOURNAL OF CANCER

Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

(2013) C. Parker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy

(2012) C. N. Sternberg et al.   ANNALS OF ONCOLOGY

A randomized, dose–response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer

(2012) S. Nilsson et al.   EUROPEAN JOURNAL OF CANCER

Recommendations for Incorporating Patient-Reported Outcomes Into Clinical Comparative Effectiveness Research in Adult Oncology

(2012) Ethan Basch et al.   JOURNAL OF CLINICAL ONCOLOGY

International field testing of the reliability and validity of the EORTC QLQ-BM22 module to assess health-related quality of life in patients with bone metastases

(2011) Edward Chow et al.   CANCER

Estimating Clinically Meaningful Changes for the Functional Assessment of Cancer Therapy—Prostate: Results from a Clinical Trial of Patients with Metastatic Hormone-Refractory Prostate Cancer

(2008) David Cella et al.   VALUE IN HEALTH